Form 8-K - Current report:
SEC Accession No. 0001437749-23-016319
Filing Date
2023-06-01
Accepted
2023-06-01 09:15:33
Documents
13
Period of Report
2023-05-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atos20230526_8k.htm   iXBRL 8-K 24475
  Complete submission text file 0001437749-23-016319.txt   156867

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atos-20230526.xsd EX-101.SCH 3602
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20230526_def.xml EX-101.DEF 11533
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20230526_lab.xml EX-101.LAB 15415
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20230526_pre.xml EX-101.PRE 11689
7 EXTRACTED XBRL INSTANCE DOCUMENT atos20230526_8k_htm.xml XML 2551
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 23983217
SIC: 2834 Pharmaceutical Preparations